{"id":453424,"date":"2021-03-09T07:03:26","date_gmt":"2021-03-09T12:03:26","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=453424"},"modified":"2021-03-09T07:03:26","modified_gmt":"2021-03-09T12:03:26","slug":"neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/","title":{"rendered":"NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">PITTSBURGH, March  09, 2021  (GLOBE NEWSWIRE) &#8212; NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (\u201cNeuBase\u201d or the \u201cCompany\u201d), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference and at the Oppenheimer 31<sup>st<\/sup> Annual Healthcare Conference. Both virtual investor conferences take place in March 2021.<\/p>\n<table style=\"border-collapse: collapse;width:880px;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\" style=\"vertical-align: top\">\n            <strong>Conference Details:<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Event:<\/td>\n<td style=\"vertical-align: top\">H.C. Wainwright Global Life Sciences Conference<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Date:<\/td>\n<td style=\"vertical-align: top\">Tuesday, March 9<sup>th<\/sup>\u00a0\u00a0\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Time:<\/td>\n<td style=\"vertical-align: top\">7:00 a.m. ET<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Location:<\/td>\n<td style=\"vertical-align: top\">\n            <a href=\"https:\/\/journey.ct.events\/view\/069cc305-d857-49c1-a550-c683b09018ad\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Webcast Link<\/a> \u2013 or at the company\u2019s website (<a href=\"https:\/\/ir.neubasetherapeutics.com\/news-events\/ir-calendar\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">click here<\/a>)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Event:<\/td>\n<td style=\"vertical-align: top\">Oppenheimer 31<sup>st<\/sup> Annual Healthcare Conference<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Date:<\/td>\n<td style=\"vertical-align: top\">Wednesday, March 17<sup>th<\/sup>\u00a0\u00a0\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Time:<\/td>\n<td style=\"vertical-align: top\">11:20 a.m. ET<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Location:<\/td>\n<td style=\"vertical-align: top\">\n            <a href=\"https:\/\/wsw.com\/webcast\/oppenheimer9\/nbse\/2706088\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Webcast Link<\/a>\u00a0\u2013 or at the company\u2019s website (<a href=\"https:\/\/ir.neubasetherapeutics.com\/news-events\/ir-calendar\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">click here<\/a>)<\/td>\n<\/tr>\n<\/table>\n<p>The webcasts from both conferences will also be archived on the NeuBase website, www.neubasetherapeutics.com.<\/p>\n<p>\n        <strong>About NeuBase Therapeutics<\/strong><br \/>\n        <br \/>NeuBase is accelerating the genetic revolution using a new class of synthetic medicines which have been shown to be able to increase, decrease and change gene function, as appropriate, to resolve causal genetic defects in living systems. NeuBase&#8217;s designer PATrOL\u2122 therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kj8DuBL2UIZCRN0tDN9L9l9vUxTn59IFuGlsZZ0-9OUyK7ilT1xFUCiMR5oJ9TupKX1uynO7QKCz6DVnNEtqH_HT-4PhH1I5CfBBhlqxmQrV2Wry1lt35HKEBEpPk138\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.neubasetherapeutics.com<\/a>.<\/p>\n<p>\n        <strong>NeuBase Investor Contact:<\/strong><br \/>\n        <br \/>Dan Ferry<br \/>Managing Director<br \/>LifeSci Advisors, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2iXmIguJVFUXt8n2guL5GZa1sUEmV3OdRw2Hpz5P6tIYYJ3l4A-lW9of-OLIQeLMOfA0-zeecUxRaGKnus-26Dp3tYJEL4Ti2rTP0A8gyZ4Y4UJ6JnojMbBWMemeyluiVfdriHZoXH3AfjRVzta_MnEyhD1xT5KIVpruUzrsqX6p-YWVk9Kq2yfDIjefKNxts3_nefGMNTecV9MJtNUnlCmIQ4f50DSIhh3456aWKsv6K4JcYN0YNjqvumylrPmS9zXWHIY98db8p0E_4DrfTI_Ps1XVaIt3LqC0ATHqr6nM4CJMti_p-kfsL8g3RllPMvpgtvVlv1eD3tc3Sr5FwASbw71nHL5c6PSQLuxgXgz0ZibI8So-Vs_KLuhxvFBF8cqbXN22V6f4Km3Ltck_mWfZj0jKCXD6rekbgy4teLUu2Iy5A_rxlvRf8dcqOIlR_ABJ8SQA2cIJflBM4XuYlVjwzeD20ViJudcD8mUa-c842_q0ZbJSiIzhRooAhLLfRfPeCkO5s51v71_886sKDA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Daniel@lifesciadvisors.com<\/a><br \/>OP: (617) 430-7576<\/p>\n<p>\n        <strong>NeuBase Media Contact:<\/strong><br \/>\n        <br \/>Cait Williamson, Ph.D.<br \/>LifeSci Public Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AQWZ0_8yvtWxM-9SWHcpkKWOMyMMW833Gr3WMyM4bvp0UZzMheGDOLuip3CQ87smQvnbOU9pJouSkfp8m_oXeFqCz2mzGoJQWYHMkhCk2UGt8gZeXKvqeKbtvUS1NYE71c7L7k6VygtFP0A3hXWePCLk19xmrUxm1gTr_Sm26fD5Z9kBukpa0VKB8dMmBEz6RcUtxP-92xsdktZ0xIfK0g2Sq5cRomdp0vHa-gPsFq2bSjHhYn0-w68C_NUVNHUKOWV0zYeXWSYAWd-d57pXVQR8luIZLBQ3Bl9r_-nbzB8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">cait@lifescipublicrelations.com<\/a><br \/>OP: (646) 751-4366<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjY3MCM0MDU0Nzc0IzUwMDA2NDg3Ng==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/71cc4bfb-07bb-4543-a756-f9d34eab49ce\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PITTSBURGH, March 09, 2021 (GLOBE NEWSWIRE) &#8212; NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (\u201cNeuBase\u201d or the \u201cCompany\u201d), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference and at the Oppenheimer 31st Annual Healthcare Conference. Both virtual investor conferences take place in March 2021. Conference Details: Event: H.C. Wainwright Global Life Sciences Conference Date: Tuesday, March 9th\u00a0\u00a0\u00a0 Time: 7:00 a.m. ET Location: Webcast Link \u2013 or at the company\u2019s website (click here) \u00a0 \u00a0 \u00a0 \u00a0 Event: Oppenheimer 31st Annual Healthcare Conference Date: Wednesday, March 17th\u00a0\u00a0\u00a0 Time: 11:20 a.m. ET Location: Webcast &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-453424","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PITTSBURGH, March 09, 2021 (GLOBE NEWSWIRE) &#8212; NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (\u201cNeuBase\u201d or the \u201cCompany\u201d), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference and at the Oppenheimer 31st Annual Healthcare Conference. Both virtual investor conferences take place in March 2021. Conference Details: Event: H.C. Wainwright Global Life Sciences Conference Date: Tuesday, March 9th\u00a0\u00a0\u00a0 Time: 7:00 a.m. ET Location: Webcast Link \u2013 or at the company\u2019s website (click here) \u00a0 \u00a0 \u00a0 \u00a0 Event: Oppenheimer 31st Annual Healthcare Conference Date: Wednesday, March 17th\u00a0\u00a0\u00a0 Time: 11:20 a.m. ET Location: Webcast &hellip; Continue reading &quot;NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-09T12:03:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjY3MCM0MDU0Nzc0IzUwMDA2NDg3Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021\",\"datePublished\":\"2021-03-09T12:03:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\\\/\"},\"wordCount\":295,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjY3MCM0MDU0Nzc0IzUwMDA2NDg3Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\\\/\",\"name\":\"NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjY3MCM0MDU0Nzc0IzUwMDA2NDg3Ng==\",\"datePublished\":\"2021-03-09T12:03:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjY3MCM0MDU0Nzc0IzUwMDA2NDg3Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjY3MCM0MDU0Nzc0IzUwMDA2NDg3Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/","og_locale":"en_US","og_type":"article","og_title":"NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021 - Market Newsdesk","og_description":"PITTSBURGH, March 09, 2021 (GLOBE NEWSWIRE) &#8212; NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (\u201cNeuBase\u201d or the \u201cCompany\u201d), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference and at the Oppenheimer 31st Annual Healthcare Conference. Both virtual investor conferences take place in March 2021. Conference Details: Event: H.C. Wainwright Global Life Sciences Conference Date: Tuesday, March 9th\u00a0\u00a0\u00a0 Time: 7:00 a.m. ET Location: Webcast Link \u2013 or at the company\u2019s website (click here) \u00a0 \u00a0 \u00a0 \u00a0 Event: Oppenheimer 31st Annual Healthcare Conference Date: Wednesday, March 17th\u00a0\u00a0\u00a0 Time: 11:20 a.m. ET Location: Webcast &hellip; Continue reading \"NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-09T12:03:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjY3MCM0MDU0Nzc0IzUwMDA2NDg3Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021","datePublished":"2021-03-09T12:03:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/"},"wordCount":295,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjY3MCM0MDU0Nzc0IzUwMDA2NDg3Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/","name":"NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjY3MCM0MDU0Nzc0IzUwMDA2NDg3Ng==","datePublished":"2021-03-09T12:03:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjY3MCM0MDU0Nzc0IzUwMDA2NDg3Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjY3MCM0MDU0Nzc0IzUwMDA2NDg3Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-upcoming-investor-conferences-in-march-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=453424"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453424\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=453424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=453424"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=453424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}